Cargando…
The challenge of finding new therapeutic avenues in soft tissue sarcomas
Soft tissue sarcomas are rare malignancies of mesenchymal origin comprising about 1% of all adult cancers. Systemic therapies for locally advanced and metastatic disease have been restricted for decades to very few effective and approved agents such as doxorubicin and ifosfamide. However, new therap...
Autor principal: | Kasper, Bernd |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457009/ https://www.ncbi.nlm.nih.gov/pubmed/31007895 http://dx.doi.org/10.1186/s13569-019-0115-4 |
Ejemplares similares
-
Beneath the Layers: Deciphering the Molecular Pathways, Therapeutic Avenues, and Neurological Connections of Soft Tissue Sarcomas
por: Ekhator, Chukwuyem, et al.
Publicado: (2023) -
Editorial: New therapeutics for soft tissue sarcomas
por: Weetall, Marla, et al.
Publicado: (2023) -
Therapeutic Targets for Bone and Soft-Tissue Sarcomas
por: Miwa, Shinji, et al.
Publicado: (2019) -
New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas
por: Seong, Gyuhee, et al.
Publicado: (2023) -
Retroperitoneal Soft Tissue Sarcoma: Emerging Therapeutic Strategies
por: de Bree, Eelco, et al.
Publicado: (2023)